In this video, Motley Fool health care analyst Max Macaluso takes a closer look at Amarin (NAS: AMRN) , which recently received approval from the Food and Drug Administration for its triglyceride-lowering drug Vascepa. The drug's excellent safety profile compared to other competitive drugs within the same space should definitely catch the eye of investors. However, because Vascepa hasn't received NCE status yet -- which would grant the company an extra two years of marketing exclusivity on top of the initial three -- enthusiasm may be somewhat tempered for the short term.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of Vascepa is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top analyst Max Macaluso's premium research report. Click here now to keep reading.

The article 1 Reason to Buy Amarin Right Now, and 1 Reason to Sell originally appeared on

Austin Smith has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Increase your money and finance knowledge from home

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Investing in Startups

The lucrative and risky world of startups.

View Course »

Add a Comment

*0 / 3000 Character Maximum